Psychiatric effects of bromocriptine and lergotrile in Parkinsonian patients.
D000368:Aged; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000139:chemically induced; D003221:Confusion / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D004569:Electroencephalography; D004873:Ergolines / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D001523:Mental Disorders / Q000139:chemically induced*; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D010554:Personality Disorders / Q000139:chemically induced; D011605:Psychoses, Substance-Induced / Q000209:etiology; D012559:Schizophrenia / Q000139:chemically induced
D004873:Ergolines; D001971:Bromocriptine